



Dr. Michael Baumann

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Dr. Michael Baumann
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 3439
Michael.Baumann@kssg.ch

Homepage

www.kssg.ch/onkologie

Units

Medizinische Onkologie und Hämatologie

Publications (15)

Fürstenau M, Thus Y, Robrecht S, Mellink C, van der Kevie-Kersemaekers A, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber P, Tadmor T, Levin M, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Janssens A, Christiansen I, Noesslinger T, Baumann M, Hebart H, Gaska T, Regelink J, Dompeling E, Lindstrom V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink A, Fischer K, Wendtner C, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann C, Hallek M, Eichhorst B, Kreuzer K, Kater A. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. *Blood* 2023

Eichhorst B, Niemann C, Kater A, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber P, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Noesslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, Klift M, Jäger U, Leys M, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink J, Widmer A, Simon F, De Silva N, Fink A, Bahlo J, Fischer K, Wendtner C, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Levin M, van Oers M, Geisler C, Stilgenbauer S, Hallek M, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. *N Engl J Med* 2023; 388:1739-1754.

Orvain C, Chantepie S, Thomas X, Escofrre-Barbe M, Huguet F, Desbrosses Y, Guillerm G, Uzunov M, Leguay T, Barbieux S, Vey N, Chevallier P, Malfuson J, Lepretre S, Baumann M, Aykut M, Chaib A, Joris M, Zerazhi H, Stussi G, Chapiro J, Berthon C, Bonmati C, Jourdan E, Carp D, Marçais A, Gallego-Hernanz M, Vaida I, Bilger K, Villate A, Pasquier F, Chalandon Y, Maury S, Lhéritier V, Ifrah N, Dombret H, Boissel N, Hunault-Berger M. Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study. *Haematologica* 2023

Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhausern R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. *Blood Adv* 2020; 4:3699-3707.

Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. *Swiss Med Wkly* 2018; 148:w14576.

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner C, Klein C, Liu N, Hallek M, Frenzel L, Krause G. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. *Int J Cancer* 2015; 137:2234-42.

Lehmann T, Hofer K, Baumann M, Hasler K, Ceschi A, Kupferschmidt H, Rohde G, Korte W. Massive human rivaroxaban overdose. *Thromb Haemost* 2014; 112:834-6.

Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. *BMC cancer* 2013; 13:153.

Baumann M, Korte W. Thrombophiliediagnostik – Entscheidungshilfe in komplexen Risikosituationen. *Cardiovasc* 2012; 6:4-6.

Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch C, Hallek M, Wendtner C, Frenzel L. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glycosylation of ceramides. *Blood* 2012; 120:3978-85.

Huober J, Widmer I, von Rohr L, Müller A, von Moos R, Güth U, Aebi S, Rochlitz C, Baumann M, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. *Oncology* 2011; 81:160-166.

Baumann M. Chronische Lymphatische Leukämie (CLL) – Von Faszination und Meilensteinen. *info@onkologie* 2011:6-10.

Baumann M, Cerny T, Sommacal A, Köberle D. Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. *Hematol Oncol* 2011

Baumann M, Thürlimann B, Ruhstaller T. Brustzentrum Kantonsspital St. Gallen – von der Multidisziplinarität zur patientinnenzentrierten interdisziplinären Betriebsorganisation. *Breast Care* 2010; 5:188-191.

Baumann M, Weder P, Köberle D. Neue Behandlungsoptionen beim metastasierten Kolorektalkarzinom – Bewertung der aktuellen Studienresultate und Konsequenzen. *Schweizer Zeitschrift für Onkologie* 2009:14-19.

Projects (14)

Eine prospektive, randomisierte, unverblindete, multizentrische Phase-III-Studie zum Vergleich der Wirksamkeit und Sicherheit von Ibrutinib Monotherapie gegen eine zeitlich begrenzte Therapie mit Venetoclax plus Obinutuzumab oder Ibrutinib plus Venetoclax bei Patienten mit bislang unbehandelter chronisch lymphatischer Leukämie (CLL) - CLL17

Clinical Studies - Dec 16, 2021 - Jul 26, 2022

Automatically Closed

VeRve: Observational study of the use of venetoclax in patients with chronic lymphocytic leukemia (CLL) under real-life setting in Austria, Germany and Switzerland (Venetoclax Real Value)

Clinical Studies - Jul 15, 2020 - Sep 27, 2022

Automatically Closed

CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP AND SAKK (THE GA101 IBRUTINIB ABT101 (GAIA) TRIAL): A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL OF STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB PLUS VENETOCLAX (RVE) VERSUS OBINUTUZUMAB (GA101) PLUS VENETOCLAX (GVE) VERSUS OBINUTUZUMAB PLUS IBRUTINIB PLUS VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION

Clinical Studies - Jul 17, 2017 - Jun 30, 2020

Automatically Closed

HOVON 103 / SAKK 30/10 protocol Tosedostat

Clinical Studies - Mar 19, 2015 - Mar 19, 2015

Automatically Closed

A phase I study of Inotuzumab Ozogamicin (CMC-544) in combination with Temsirolimus (CCI-779) in patients with relapsed or refractory CD22-positive B-cell Non Hodgkin's Lymphomas

Clinical Studies - Oct 8, 2012 - Dec 31, 2013

Automatically Closed

Master Protokoll: A Program of randomized phase II multicenter studies to assess the tolerability and efficacy of the addition of new drugs to standard induction chemotherapy in AML and RAEB \geq 66 years and very poor risk AML \geq years

Clinical Studies - Feb 9, 2012 - Feb 9, 2016

Automatically Closed

Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia

Clinical Studies - May 31, 2010 - Jan 31, 2015

Automatically Closed

A randomized, multicenter, phase III open-label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine and Lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior Trastuzumab-based therapy

Clinical Studies - Oct 20, 2009 - Jun 30, 2011

Completed

Local antiperspirant for prevention of palmar-plantar erythrodysesthesia (PPE) in patients treated with pegylated liposomal doxorubin: A randomized, multicenter, double blinded, phase III trial

Clinical Studies - Sep 23, 2009 - Jun 30, 2011

Completed

Ein Phase III Studienprogramm zur Kombination von Bevacizumab, Everolimus (RAD001) oder Lapatinib mit einer neoadjuvanten Chemotherapie bei primärem Mammakarzinom

Clinical Studies - Jun 30, 2009 - Jun 30, 2012

Completed

A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer

Clinical Studies - Jun 1, 2005 - Sep 30, 2015

Completed

Trastuzumab monotherapy followed by the combination of trastuzumab and letrozole in post-menopausal women with ER-positive, HER-2 positive advanced breast cancer resistant to a nonsteroidal aromatase inhibitor

Clinical Studies - Jan 1, 2005 - Mar 30, 2011

Automatically Closed

Maintenance Chemotherapy in Hormone Non-Responsive Breast Cancer

Clinical Studies - Feb 1, 2001 - Feb 1, 2015

Automatically Closed

Randomized phase III trial of Herceptin™ followed by Taxol plus Herceptin™ versus the combination of Herceptin™ and Taxol as palliative chemotherapy in patients with HER2-overexpressing advanced breast cancer

Clinical Studies - Nov 1, 1999 - Nov 1, 2015

Automatically Closed